JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (50)
2022
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
2021
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
2019
2017
-
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma
British Journal of Haematology, Vol. 178, Núm. 4, pp. 547-560
-
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
British Journal of Haematology, Vol. 178, Núm. 6, pp. 896-905
2015
-
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study
American Journal of Hematology, Vol. 90, Núm. 4, pp. 314-319
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
2014
-
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600
-
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206
-
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
Blood, Vol. 123, Núm. 26, pp. 4136-4142
2013
-
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma
Journal of Clinical Oncology
-
Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Leukemia, Vol. 27, Núm. 4, pp. 780-791
2012
-
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: Results from the VISTA trial
European Journal of Haematology, Vol. 89, Núm. 1, pp. 16-27
-
IMWG consensus on maintenance therapy in multiple myeloma
Blood, Vol. 119, Núm. 13, pp. 3003-3015
-
Phase i studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
Investigational New Drugs, Vol. 30, Núm. 3, pp. 1121-1131
-
Proteasome inhibitors in multiple myeloma: 10 Years later
Blood, Vol. 120, Núm. 5, pp. 947-959
2011
-
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial
British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221
-
Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
Blood